You are here

ALX148

ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

BioSpace

Tue, 09/22/20 - 12:06 pm

head and neck cancer

After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer hopeful

Fierce Biotech

Tue, 02/18/20 - 10:55 am

head and neck cancer

ALX raises $105M for midphase trials of CD47 cancer drug

Fierce Biotech

Wed, 02/12/20 - 10:31 am